Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Herpes Labialis (Oral Herpes) - Overview
Herpes Labialis (Oral Herpes) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Herpes Labialis (Oral Herpes) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development
AiCuris GmbH & Co KG
Astellas Pharma Inc
Brandenburg Antiinfektiva GmbH
Dobecure SL
Heidelberg Immunotherapeutics Gmbh
noViricides Inc
Provention Bio Inc
Ratiol Vaccines Inc
Shulov Innovative Science Ltd
Squarex LLC
Vironova Medical AB
Herpes Labialis (Oral Herpes) - Drug Profiles
amemevir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ethamsylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HDIT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVHHV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pritelivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRV-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RVX-101HSV1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Herpes Labialis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
squaric acid dibutyl ester - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Labialis (Oral Herpes) - Dormant Projects
Herpes Labialis (Oral Herpes) - Discontinued Products
Herpes Labialis (Oral Herpes) - Product Development Milestones
Featured News & Press Releases
Aug 05, 2019: Squarex announces positive results from completed phase 2 study of SQX770 in the prevention of recurrent herpes labialis
Jul 01, 2019: Squarex appoints biopharmaceutical industry veteran Jack V. Talley as chief executive officer
Feb 14, 2019: Squarex Announces Publication of Clinical Results for SQX770 for the Prevention of Herpes Outbreaks in Immunity, Inflammation and Disease
Aug 23, 2017: AiCuris Announces Fil Patient Treated in Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
May 24, 2017: Cold Sore Treatment Developed by Squarex Shown Effective by Immunotherapy Study
Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by AiCuris GmbH & Co KG, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by Astellas Pharma Inc, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by Brandenburg Antiinfektiva GmbH, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by Dobecure SL, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by Heidelberg Immunotherapeutics Gmbh, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides Inc, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by Provention Bio Inc, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by Rational Vaccines Inc, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by Squarex LLC, H2 2020
Herpes Labialis (Oral Herpes) - Pipeline by Vironova Medical AB, H2 2020
Herpes Labialis (Oral Herpes) - Dormant Projects, H2 2020
Herpes Labialis (Oral Herpes) - Discontinued Products, H2 2020